BCL2 and neoplasm: BET inhibitors have the capability to selectively modulate the expression of NOTCH3 by targeting BRD4 and affect its downstream effector genes.92 Liu et al. showed that BET inhibitors can upregulate the pro-apoptotic factor BIM (BCL2L11) (of the BCL2 family), cause tumor cells to undergo apoptosis via the mitochondrial apoptotic pathway, and inhibit tumor cell invasion and migration through the STAT3 pathway by downregulating its phosphorylation.